

Claims

1. A pharmaceutical composition comprising a cannabinoid component and a terpene component, the composition comprising:
 - (a) a cannabinoid component comprising Δ^9 -tetrahydrocannabinol (THC), cannabidiol (CBD) wherein the cannabinoid component comprises:
 - i) $\geq 40\%$ w/w Δ^9 -tetrahydrocannabinol (THC),
 - ii) $\leq 50\%$ w/w cannabidiol (CBD),
 - iii) $\geq 0.15\%$ w/w Cannabigerol (CBG),
 - iv) $\leq 0.5\%$ w/w Cannabinodiol (CBN); and
 - (b) a terpene component comprising:
 - i) β -caryophyllene in an amount of $\geq 0.4\%$ w/w of the composition,
 - ii) d-limonene in an amount of $\geq 0.2\%$ w/w of the composition, and
 - iii) β -pinene in an amount of $\geq 0.15\%$ w/w of the composition.
2. The pharmaceutical composition according to claim 1 wherein the ratio of THC:CBD is about 2:1 to about 1:1.
3. The pharmaceutical composition according to claim 2 wherein the ratio of THC:CBD/CBG is about 1:1.
4. The pharmaceutical composition according to any one of claims 1 to 3 wherein the cannabinoid component is present in an amount of about 1% to about 10% w/w of the composition.
5. The pharmaceutical composition according to claim 4 wherein the cannabinoid component is present in an amount of about 2.5 to about 3.5 % w/w of the composition.
6. The pharmaceutical composition according to any one of claims 1 to 5 wherein the terpene component is present in an amount of about 0.75 % w/w to about 10% w/w of the composition.

7. The pharmaceutical composition according to claim 6 wherein the terpene component is present in an amount of about 0.75% w/w to about 1.25 % w/w of the composition.
8. The pharmaceutical composition according to any one of claims 1 to 7 wherein the β -caryophyllene is present in an amount of about 0.4% w/w to about 5% w/w of the composition
9. The pharmaceutical composition according to claim 8 wherein the β -caryophyllene is present in an amount of about 0.4% w/w to about 0.5% w/w of the composition.
10. The pharmaceutical composition according to any one of claims 1 to 9 wherein the d-limonene is present in an amount of about 0.2% w/w to about 5% w/w of the composition.
11. The pharmaceutical composition according to claim 10 wherein the d-limonene is present in an amount of about 0.2% w/w to about 0.3% w/w of the composition.
12. The pharmaceutical composition according to any one of claims 1 to 11 wherein the β -pinene is present in an amount of about 0.15% w/w to about 5% w/w of the composition.
13. The pharmaceutical composition according to claim 12 wherein the β -pinene is present in an amount of about 0.15% w/w to about 0.25% w/w of the composition.
14. A method of treating chronic pain, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of any one of claims 1 to 13.
15. Use of a composition of any one of claims 1 to 13 in the manufacture of a medicament for treating chronic pain.
16. A pharmaceutical composition according to any one of claims 1 to 13 for use in treating chronic pain.
17. The method according to claim 14, the use according to claim 15 or the composition according to claim 16 wherein the subject is an athlete or retired athlete.
18. The method, use or composition according to any one of claims 14 to 17 wherein the chronic pain is a result of injury sustained during training or sport.

19. The method, use or composition according to any one of claims 14 to 17 wherein the chronic pain is a result of over use or repetitive action that develops over time.
20. The method, use or composition according to any one of claims 14 to 17 wherein the chronic pain is arthritic pain, back pain, joint pain, inflammatory pain or nerve pain.